Stemline Therapeutics (STML) Downgraded by Zacks Investment Research

Stemline Therapeutics (NASDAQ:STML) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Friday.

According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “

Several other analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price target on shares of Stemline Therapeutics in a research note on Friday, February 2nd. ValuEngine raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, BidaskClub raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $33.75.

Shares of Stemline Therapeutics (NASDAQ:STML) traded down $0.70 during trading hours on Friday, hitting $15.35. The stock had a trading volume of 191,701 shares, compared to its average volume of 343,192. Stemline Therapeutics has a one year low of $6.35 and a one year high of $17.40. The firm has a market cap of $478.04, a price-to-earnings ratio of -6.05 and a beta of -0.02.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.11). The company had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.30 million. Stemline Therapeutics had a negative net margin of 4,689.63% and a negative return on equity of 75.50%. sell-side analysts anticipate that Stemline Therapeutics will post -2.68 EPS for the current fiscal year.

In other news, insider David Gionco sold 4,250 shares of the business’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $13.43, for a total transaction of $57,077.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Kenneth Hoberman sold 14,040 shares of the business’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $13.93, for a total value of $195,577.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,216 shares of company stock valued at $591,925. 16.70% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Teachers Advisors LLC increased its holdings in Stemline Therapeutics by 1.3% in the second quarter. Teachers Advisors LLC now owns 43,397 shares of the biopharmaceutical company’s stock valued at $399,000 after purchasing an additional 541 shares during the last quarter. Nationwide Fund Advisors increased its holdings in Stemline Therapeutics by 7.2% in the second quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 855 shares during the last quarter. Rhumbline Advisers increased its holdings in Stemline Therapeutics by 18.5% in the second quarter. Rhumbline Advisers now owns 27,358 shares of the biopharmaceutical company’s stock valued at $252,000 after purchasing an additional 4,280 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Stemline Therapeutics by 40.1% in the second quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 5,522 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in Stemline Therapeutics by 17.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 47,025 shares of the biopharmaceutical company’s stock valued at $734,000 after purchasing an additional 6,825 shares during the last quarter. Institutional investors own 43.87% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Stemline Therapeutics (STML) Downgraded by Zacks Investment Research” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/09/stemline-therapeutics-stml-downgraded-by-zacks-investment-research.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply